DJIA 18,126.12 -36.87 -0.20%
NASDAQ 5,097.98 -8.62 -0.17%
S&P 500 2,120.79 -2.69 -0.13%
market minute promo

MannKind Corp (NASDAQ: MNKD)

5.20 -0.07 (-1.33%)

REAL-TIME: Last trade at

Extended Hours: $5.20 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

MNKD $5.20 -1.33%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $5.20
Previous Close $5.27
Daily Range $5.05 - $5.27
52-Week Range $3.46 - $11.48
Market Cap $2.1B
P/E Ratio -11.71
Dividend (Yield) $0.00 (0.0%)
Volume 8,381,178
Average Daily Volume 7,388,959
Current FY EPS -$0.31




Drug Makers

MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website:

News & Commentary

How Will Big Pharma Fight Back Against MannKind?

Afrezza, an inhaled insulin, is officially on the market, and threatens many big industry leaders. How will big pharma fight back against the inhaled insulin threat?

MNKD July 10th Options Begin Trading

Wednesday's ETF Movers: BBH, XOP

Could Incoming Threats Sink MannKind Corporation?

Big Pharma suspected that MannKind's Afrezza would make its way to the market eventually. Now that its here, what does the industry have in its pipeline that could potentially slow adoption?

Interesting MNKD Put And Call Options For July 2nd

MannKind, Front and Center: The Best Product Doesn’t Always Equal the Best Stock

The Motley Fool's own Michael Douglass and Todd Campbell dig into MannKind Corp.'s first quarter earnings to see if MannKind is a bargain, or a bust.

MannKind's Afrezza Inhaled Insulin: A Game Changer For Seniors With Diabetes

Has MannKind Stock Finally Bottomed Out?

My Primary Care Provider's Take On Afrezza

MannKind Corporation: Afrezza Is Better Than Weak Launch Suggests

See More MNKD News...

MNKD's Top Competitors

MNKD $5.20 (-1.33%)
Current stock: MNKD
AMGN $157.35 (-1.93%)
Current stock: AMGN
GILD $112.85 (0.35%)
Current stock: GILD
BIIB $400.10 (-0.70%)
Current stock: BIIB